Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on creating medicines that make a difference for patients. The Company’s lead product, linaclotide provides patients and healthcare practitioners with a treatment option for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), GI disorders that affect millions of sufferers across the world. Linaclotide is available to adult men and women suffering from IBS-C, or CIC, in the United States under the trademarked name LINZESS, and to adult men and women suffering from IBS-C in the European Union (the E.U.), under the trademarked name CONSTELLA. The Company’s partner Astellas initiated a double-blind, placebo-controlled Phase III clinical trial of linaclotide in adult patients with IBS-C.